ANTX - Company ID 0001880438
The table below shows AN2 Therapeutics, Inc.'s balance sheet line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & equivalents | $19.94M | $21.35M | $15.65M | $27.22M |
| Short-term investments | - | - | - | - |
| Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Total current assets | $59.94M | $86.26M | $110.51M | $98.62M |
| Property, plant & equipment | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Goodwill | - | - | - | - |
| Total assets | $61.95M | $92.09M | $138.74M | $102.56M |
| Accounts payable | $3.02M | $3.32M | $2.68M | $2.12M |
| Total current liabilities | $8.72M | - | $14.04M | $7.19M |
| Long-term debt | - | - | - | - |
| Total liabilities | $8.89M | $10.24M | $14.04M | $7.19M |
| Retained earnings | -$240.95M | -$205.78M | -$154.46M | -$89.72M |
| Total equity | $53.06M | $81.85M | $124.70M | $95.37M |